title: Hydrolysis of factor VIII mediated by catalytic antibodies occurs in haemophilia A patients with or without factor VIII inhibitors.
abstract: The major complication of the substitutive treatment of haemophilia A (HA) is the development of antifactor VIII (FVIII) antibodies. Most of these antibodies neutralize FVIII procoagulant activity, and are identified as FVIII inhibitor. A subgroup of these antibodies, 'catalytic antibodies', catalyses the FVIII hydrolysis. We investigated the frequency and the activity of catalytic antibodies, according to the phenotype of HA and the presence or absence of FVIII inhibitor. IgG from 16 patients with inhibitor and 17 patients without inhibitor were purified. Rates of FVIII hydrolysis and inhibitor titres were evaluated. Anti-FVIII catalytic antibodies were detected in 63.6% of patients with HA, irrespective of the HA phenotype and the presence of FVIII inhibitor. The frequency was significantly higher for severe HA patients (73.3%) and patients with inhibitor (87.5%), but their FVIII-proteolytic activity was not significantly different from patients with mild or moderate HA and patients without inhibitor. The evolution of both catalytic and inhibitory activities was studied for 11 patients with FVIII inhibitor. We observed two profiles. In the profile 1, 18.2% of patients, the catalytic activity and the inhibitor titre coevolved. In contrast, a dissociated evolution of these two parameters was observed in 72.8% patients in profile 2. These data confirm the importance of anti-FVIII catalytic activity in patients with severe, moderate and mild HA. Interestingly, most of the patients presented a dissociated profile, suggesting that anti-FVIII antibodies might not systematically act as FVIII inhibitors.
authors.affiliation: Department of Hematology, CHU de Caen, Caen, France.
authors.forename: S S
authors.initials: SS
authors.lastname: Grosbois
authors.forename: M F
authors.initials: MF
authors.lastname: Brionne
authors.forename: A L F
authors.initials: AL
authors.lastname: de Longcamp
authors.forename: P
authors.initials: P
authors.lastname: Gautier
authors.forename: S
authors.initials: S
authors.lastname: V Kaveri
authors.forename: A
authors.initials: A
authors.lastname: Borel-Derlon
authors.forename: Y
authors.initials: Y
authors.lastname: Repessé
mesh_terms: D000704:Analysis of Variance; D057134:Antibodies, Neutralizing / Q000097:blood*; D005169:Factor VIII / Q000276:immunology* / Q000378:metabolism / Q000627:therapeutic use; D006467:Hemophilia A / Q000188:drug therapy / Q000276:immunology* / Q000378:metabolism; D006801:Humans; D006868:Hydrolysis; D007074:Immunoglobulin G / Q000097:blood; D008297:Male; D012189:Retrospective Studies
chemical_list: D057134:Antibodies, Neutralizing; D007074:Immunoglobulin G; D005169:Factor VIII